Supplementary Materials

Supplementary Material for:

Chimpanzee adenovirus– and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults

Christopher A. Green,* Elisa Scarselli, Charles J. Sande, Amber J. Thompson, Catherine M. de Lara, Kathryn S. Taylor, Kathryn Haworth, Mariarosaria Del Sorbo, Brian Angus, Loredana Siani, Stefania Di Marco, Cinzia Traboni, Antonella Folgori, Stefano Colloca, Stefania Capone, Alessandra Vitelli, Riccardo Cortese, Paul Klenerman, Alfredo Nicosia, Andrew J. Pollard

*Corresponding author. E-mail: christopher.green{at}paediatrics.ox.ac.uk

Published 12 August 2015, Sci. Transl. Med. 7, 300ra126 (2015)
DOI: 10.1126/scitranslmed.aac5745

This PDF file includes:

  • Fig. S1. Ethnicity and baseline physical and demographic characteristics of the 42 enrolled volunteers.
  • Fig. S2. CONSORT flow diagram for recruitment and completion of the study.
  • Fig. S3. Kinetics of the serum neutralizing antibody response to vaccination for each individual.
  • Fig. S4. Supplementary ASC data derived from ELISpot.
  • Fig. S5. Supplementary T cell IFN-γ data derived from ELISpot.
  • Fig. S6. The distribution of peptide pool responses before and after vaccination.
  • Fig. S7. The gating strategy used to quantify immune response from ICS FACS data.
  • Fig. S8. The number of CD4+ and CD8+ IFN-γ responses after boost.
  • Fig. S9. CD4+ and CD8+ IL-2 responses before and after vaccination.
  • Fig. S10. CD4+ and CD8+ TNFα responses before and after vaccination.
  • Fig. S11. CD4+ and CD8+ IL-5 responses before and after vaccination.
  • Fig. S12. IL-6 and IL-17 responses before and after vaccination.
  • Fig. S13. Serum PanAd3 neutralizing antibody titers and volunteer age.
  • Fig. S14. Correlation plots between anti-PanAd3 neutralizing antibody titers before prime and boost vaccination and the magnitude of subsequent immune responses.
  • Table S1. Summary of the eligibility criteria for study volunteers.
  • Table S2. Serious adverse event (SAE) descriptions.
  • Table S3. Hematological changes within 1 week after boost vaccination; two volunteers with clinically significant concurrent drops in hematological indices.
  • Table S4. Supplementary safety data.
  • Table S5. Supplementary data on the RSV-specific immune response to vaccination.

[Download PDF]